Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

1663

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis Atopic

Interventions

DRUG: Amlitelimab
DRUG: Topical corticosteroids
DRUG: Topical calcineurin inhibitors
DRUG: Oral corticosteroids

Sponsor

Sanofi